Due to some treatment limitations of premixed insulin formulations/options (i.e. inability to adjust the long- and short-acting components separately or adequately treat post-lunch and early-morning hyperglycemia) (24), fixed-ratio co-formulation insulin-based products have been developed that combine a basal and a rapid-acting insulin in a formulation where the two components act independently allowing a simpler insulin regimen with fewer injections alongside basal and prandial insulin coverage (23, 27, 28). Here, INS is linked to Hyperglycemia.